Technical Analysis for CTX - Crescita Therapeutics Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.430 | -2.27% | -0.010 |
Earnings due: May 9
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 50 DMA | Bearish | 0.00% | |
| Narrow Range Bar | Range Contraction | -2.27% | |
| Crossed Above 50 DMA | Bullish | -2.27% | |
| 180 Bullish Setup | Bullish Swing Setup | -2.27% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | -1.15% | |
| MACD Bullish Centerline Cross | Bullish | -1.15% | |
| Narrow Range Bar | Range Contraction | -1.15% | |
| Gapped Up | Strength | -1.15% | |
| MACD Bearish Centerline Cross | Bearish | 2.38% |
| Alert | Time |
|---|---|
| 1.5x Volume Pace | about 15 hours ago |
| Rose Above Previous Day's High | 2 days ago |
| Rose Above 10 DMA | 2 days ago |
| Up 2% | 2 days ago |
| Up 1% | 2 days ago |
Get a Trading Assistant
- Earnings date: 2024-05-09
Crescita Therapeutics Inc. Description
Crescita Therapeutics Inc. is a drug development company. The Company owns products for treating medical conditions in dermatology and pain. It owns various drug delivery platforms, which include Durapeel and Foam technology to support the development of patented formulations that can deliver actives into or through the skin. It operates two business units: the Topical Products and Technology (TPT) Group and the Immunology Group. The TPT Group product, Pliaglis and other products are focused on dermatology and pain. Its product Flexicaine is in Phase II clinical stage and has therapeutic area in Tick-borne disease. Its product Ibuprofen Foam is in pre-clinical stage and has therapeutic area in Acute Pain. Its product Terbinafine is in pre-clinical stage and has therapeutic area in Onychomycosis. Its product Mical 1 is in pre-clinical stage and has therapeutic area in Psoriasis. Its product Mical 2 is in pre-clinical stage and has therapeutic area in Dermatological skin treatment.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Delivery Clinic Drug Pain Disease RTT Drugs Skin Medical Specialties Organ Systems Immunology Drug Delivery Drug Development Acute Pain Dermatology Psoriasis Onychomycosis Topical Products
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.79 |
| 52 Week Low | 0.36 |
| Average Volume | 16,443 |
| 200-Day Moving Average | 0.559 |
| 50-Day Moving Average | 0.435 |
| 20-Day Moving Average | 0.430 |
| 10-Day Moving Average | 0.431 |
| Average True Range | 0.012 |
| RSI (14) | 49.75 |
| ADX | 17.34 |
| +DI | 39.389 |
| -DI | 39.153 |
| Chandelier Exit (Long, 3 ATRs) | 0.453 |
| Chandelier Exit (Short, 3 ATRs) | 0.412 |
| Upper Bollinger Bands | 0.464 |
| Lower Bollinger Band | 0.396 |
| Percent B (%b) | 0.5 |
| BandWidth | 15.682 |
| MACD Line | 0.002 |
| MACD Signal Line | 0.000 |
| MACD Histogram | 0.0016 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.445 | ||||
| Resistance 3 (R3) | 0.447 | 0.443 | 0.443 | ||
| Resistance 2 (R2) | 0.443 | 0.440 | 0.443 | 0.442 | |
| Resistance 1 (R1) | 0.437 | 0.437 | 0.435 | 0.435 | 0.441 |
| Pivot Point | 0.433 | 0.433 | 0.433 | 0.433 | 0.433 |
| Support 1 (S1) | 0.427 | 0.430 | 0.425 | 0.425 | 0.419 |
| Support 2 (S2) | 0.423 | 0.427 | 0.423 | 0.418 | |
| Support 3 (S3) | 0.417 | 0.423 | 0.418 | ||
| Support 4 (S4) | 0.415 |
